●在授权范围内，本次实施的担保金额及已实际为其提供的担保余额（包含尚未使用的额度）： | 担保 | 被担保方 | 被担保方 最近一期 | 授信银行 | 担保 | 本次担保前 已为其提供 | 本次担保 金额（万 | 备注 | 股东大会授 权担保额度 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 方 | | 资产负债 | | 期限 | 的担保余额 | | | | | | | | | | | 元） | | (万元) | | | | 率 | | | （万元） | | | | | 人福 医药 | 宜昌人福 | 22.93% | 湖北三峡农村 商业银行股份 | 年 | ¥135,240.00 | ¥30,000.00 | 本次担保将替 换前期已为其 30,000 | ¥220,000.00① | | | | | 有限公司伍家 | 3 | | | 提供的 | | | | | | 支行 | | | | 万元担保额度 | | 1 1、宜昌人福药业有限责任公司（以下简称"宜昌人福"）； 2、新疆维吾尔药业有限责任公司（以下简称"新疆维药"）； 3、宜昌三峡 ...

证券代码：600079 证券简称：人福医药 编号：临 2024-117 号 人福医药集团股份公司董事会 关于为控股子公司提供关联担保的公告 特 别 提 示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 重要内容提示 ● 被担保人名称：湖北葛店人福药业有限责任公司（以下简称"葛店人福"） 注：①股东大会授权人福医药预计为葛店人福及其下属资产负债率高于或等于 70%的全资或控股子公 司提供的最高担保额度为 123,000.00 万元。 ● 本次担保是否有反担保：被担保的控股子公司将提供反担保以增强对上市公司的保障。 ● 对外担保逾期的累计数量：无。 ● 特别风险提示：截至本公告披露之日，人福医药集团股份公司（简称"人福医药"或"公 司"、"上市公司"）及全资或控股子公司对外担保总额（包含尚未使用的额度）为 865,034.40 万元，占公司最近一期经审计的净资产 1,704,360.00 万元的 50.75%，全部为对公司及下属全 资或控股子公司提供的担保。其中上市公司及子公司对下属全资或控股子公司提供的担保总 额（包含尚未使 ...

减持计划的实施结果情况：2024 年 7 月 27 日，公司披露了董事长李杰先生减 持股份计划公告，李杰先生因 2020 年发行股份购买资产形成纳税义务，存在缴纳个 人所得税的资金需求，拟自减持计划公告披露之日起 15 个交易日后的 3 个月内，通 过上海证券交易所证券交易系统以集中竞价方式或大宗交易方式减持不超过 12,000,000 股，占公司总股本的 0.74%，占其持股比例的 12.31%。截至本公告披露之 日，本次减持计划的减持时间区间届满，李杰先生累计减持公司股份 10,732,900 股， 占公司总股本的比例为 0.66%。 上述减持主体无一致行动人。 1 股东名称 股东身份 持股数量（股） 持股比例 当前持股股份来源 李杰 5%以上非第 一大股东 97,480,104 5.97% 非公开发行取得：1,792,114 股 发 行 股 份 购 买 资 产 取得： 90,804,390 股 集中竞价交易取得：2,483,600 股 其他方式取得：2,400,000 股 一、减持主体减持前基本情况 证券代码：600079 证券简称：人福医药 公告编号：2024-114 人福医药集团股份公司 董事长减持 ...

Investment Rating - The report gives a "Buy" rating for the company, indicating a positive outlook based on the anticipated financial performance and strategic initiatives [4][9]. Core Insights - The company has been implementing a "core business focus" strategy since 2017, leading to a significant reduction in debt and improvement in financial metrics, including a decrease in the debt-to-asset ratio to 43.7% as of Q3 2024, down from a peak of 60% [4][37]. - The company has shown a strong improvement in net profit margins, with a non-recurring net profit margin increasing from 2.2% in 2019 to 7.4% in 2023, and a compound annual growth rate (CAGR) of 21.8% in non-recurring net profit from 2017 to 2023 [4][37]. - The core subsidiary, Yichang Renfu, has demonstrated robust performance, with revenue growing from 1.4 billion yuan in 2012 to 8.06 billion yuan in 2023, reflecting a CAGR of 17.2% [4][44]. Summary by Sections 1. Core Business Focus Strategy - The company has successfully divested non-core assets and focused on its main business, leading to improved financial health and operational efficiency [4][37]. - The financial cost ratio has decreased significantly, from 4.1% in 2019 to 1.2% in 2023, contributing to enhanced profitability [4][37]. 2. Anesthesia Market Potential - The anesthesia market is expected to grow due to an aging population and increasing demand for comfortable medical procedures, with the domestic market size estimated at around 30 billion yuan [58][60]. - Yichang Renfu holds a dominant market share in the analgesic sector, with over 90% market share in key products like the Fentanyl series [11][58]. 3. Non-Surgical Growth and New Product Potential - The company is focusing on non-surgical areas, with significant growth in non-surgical anesthesia revenue, which increased from approximately 600 million yuan in 2019 to 2.04 billion yuan in 2023, reflecting a CAGR of 35.8% [4][11]. - New products in the sedation field, launched since 2020, are expected to accelerate growth in this segment, with projected revenue growth of 10-15% over the next three years [4][11]. 4. Research and Development - The company has increased its R&D expenditure to 1.46 billion yuan in 2023, with an R&D expense ratio of 5.96%, up from 2.69% in 2019, indicating a commitment to innovation [4][53]. - Several promising products are in various stages of clinical trials, which could further enhance the company's product pipeline and market position [4][55]. 5. Financial Forecast and Valuation - The company is projected to achieve revenues of 26.05 billion yuan, 27.96 billion yuan, and 29.94 billion yuan for 2024, 2025, and 2026, respectively, with corresponding growth rates of 6.2%, 7.3%, and 7.1% [9][4]. - The expected net profits for the same period are 2.17 billion yuan, 2.57 billion yuan, and 2.97 billion yuan, with growth rates of 1.5%, 18.4%, and 15.7% [9][4].

[Table_MainInfo] 公司研究/医药与健康护理/化学制药 证券研究报告 人福医药（600079）公司季报点评 2024 年 11 月 05 日 请务必阅读正文之后的信息披露和法律声明 [Table_InvestInfo] 投资评级 优于大市 维持 | --- | --- | |-------------------------------------------------------------|-------------| | 股票数据 | | | 11 [ Table_StockInfo 月 05 日收盘价（元） ] | 21.26 | | 52 周股价波动（元） | 15.68-27.36 | | 总股本 / 流通 A 股（百万股） | 1632/1543 | | 总市值 / 流通市值（百万元） | 34701/32808 | | 相关研究 | | | [Table_ReportInfo] 《宜昌人福销售规模和经营效益稳步提升》 | | | 2024.07.29 | | | 《非手术科室高速增长，宜昌人福稳健前行》 | | | 2024.04.03 | | | 《 经 营 平 稳 有 序 ...

公 司 研 究 2024 年 11 月 04 日 公司点评 买入/维持 人福医药(600079) 昨收盘:21.17 医药 人福医药：大股东重整取得进展，核心业务稳健增长 走势比较 (40%) (28%) (16%) (4%) 8% 20% 23/11/624/1/1724/3/2924/6/924/8/20 24/10/31 人福医药 沪深300 事件：2024 年 10 月 30 日，公司发布 2024 年第三季度报告: 公司前 三季度营业收入 191.43 亿元，同比增长 5.70%；归母净利润 15.90 亿元， 同比下降 10.12%（上年同期公司出售资产及债务重组实现非经常性损益 2.66 亿元）；扣非归母净利润 15.21 亿元，同比增长 1.21%，剔除汇兑损益 影响后，扣非归母净利润 15.88 亿元，同比增长 10.13%。 其中，2024 年第三季度营业收入 62.82 亿元，同比增长 9.66%，归母 净利润 4.79 亿元，同比增长 7.57%，扣非归母净利润 4.32 亿元，同比增 长 0.04%。 大股东重整取得积极进展，重整方案有望 2025H1 落地 2024 年 10 月 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][3]. Core Insights - The company has shown steady revenue growth, with a notable performance in its core anesthesia business. For the first three quarters of 2024, the company reported revenue of 19.143 billion yuan, a year-on-year increase of 5.70%. However, the net profit attributable to shareholders decreased by 10.12% to 1.590 billion yuan, while the net profit excluding non-recurring items increased by 1.21% to 1.521 billion yuan. The gross margin for this period was 46.76%, up by 0.90 percentage points, and the net margin was 11.01%, down by 1.60 percentage points [3][4]. Financial Performance Summary - For the first three quarters of 2024, the company achieved: - Revenue: 191.43 billion yuan (YoY +5.70%) - Net profit attributable to shareholders: 15.90 billion yuan (YoY -10.12%) - Net profit excluding non-recurring items: 15.21 billion yuan (YoY +1.21%) - Gross margin: 46.76% (YoY +0.90 percentage points) - Net margin: 11.01% (YoY -1.60 percentage points) [3][4]. Business Segment Performance - The company is actively promoting its "core focus" strategy, enhancing the core competitiveness of its subsidiaries. For instance, Yichang Renfu achieved revenue of 6.77 billion yuan in the first three quarters of 2024, a 13% increase YoY, with a net profit of 1.74 billion yuan, up 20% YoY. The sales revenue from the central nervous system pharmaceuticals reached approximately 5.65 billion yuan, growing about 12% YoY [4][5]. Anesthesia Business Outlook - The demand for outpatient anesthesia is increasing, and the anesthesia business is expected to continue its upward trend. Key products such as sufentanil and remifentanil have shown significant sales growth, with revenues of over 1.5 billion yuan (YoY +18%) and approximately 2.17 billion yuan (YoY +8%), respectively. The company is also expanding the application of anesthetics in ICU settings and promoting them for painless procedures in gastroenterology, obstetrics, and interventional treatments [5][6]. Financial Forecast - The company maintains its profit forecasts for 2024-2026, expecting net profits attributable to shareholders to be 2.460 billion yuan, 3.046 billion yuan, and 3.627 billion yuan, respectively. The earnings per share (EPS) are projected to be 1.51 yuan, 1.87 yuan, and 2.22 yuan per share, with corresponding price-to-earnings (P/E) ratios of 12.9, 10.4, and 8.7 times [3][6].

证券时报e公司讯，人福医药(600079)10月31日晚间公告，控股子公司宜昌人福近日收到国家药品监督 管理局核准签发的复方醋酸钠林格注射液的《药品注册证书》。 复方醋酸钠林格注射液用于循环血量及组织间液减少时的细胞外液的补充，代谢性酸中毒的纠正。 ...

证券代码：600079 证券简称：人福医药 编号：临 2024-113 号 人福医药集团股份公司 关于复方醋酸钠林格注射液获得药品注册证书的公告 特 别 提 示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 人福医药集团股份公司（以下简称"公司"或"人福医药"）控股子公司宜昌人 福药业有限责任公司（以下简称"宜昌人福"，公司持有其80%的股权）近日收到国 家药品监督管理局核准签发的复方醋酸钠林格注射液的《药品注册证书》。现将批件 主要内容公告如下： 一、药品名称：复方醋酸钠林格注射液 五、注册分类：化学药品3类 十一、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本 品符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、标 签及生产工艺照所附执行。药品生产企业应当符合药品生产质量管理规范要求方可生 产销售。 复方醋酸钠林格注射液用于循环血量及组织间液减少时的细胞外液的补充，代谢 性酸中毒的纠正。宜昌人福将复方醋酸钠林格注射液委托给公司全资子公司宜昌三峡 制药有限公司生产。宜昌人福于2022 ...

Investment Rating - The investment rating for Renfu Pharmaceutical is "Buy" (maintained) [2][3]. Core Views - The company's revenue for the first three quarters of 2024 reached 19.143 billion yuan, a year-on-year increase of 5.7%, while the net profit attributable to shareholders was 1.590 billion yuan, a decrease of 10.12% year-on-year [2]. - The restructuring of the controlling shareholder's debt is accelerating, which is expected to lead to a valuation recovery for the company [2]. - The proportion of revenue from non-surgical anesthesia continues to increase, indicating potential for future growth [2]. - The company has invested approximately 1.093 billion yuan in R&D in the first three quarters, supporting its innovation transformation [2]. Summary by Sections Financial Performance - In Q3 2024, the company's revenue was 6.282 billion yuan, up 9.66% year-on-year, with net profits of 479 million yuan and 432 million yuan for attributable and non-recurring net profits, respectively [2]. - For 2024, the company expects revenues of 26.012 billion yuan, a growth rate of 6%, and net profits of 2.208 billion yuan, a growth rate of 3.43% [3]. Shareholder Restructuring - The major shareholder, Wuhan Contemporary Technology, has initiated bankruptcy restructuring, which is expected to positively impact the company's valuation [2]. Anesthesia Revenue Growth - The revenue from non-surgical anesthesia has been increasing, with 6.7 billion yuan in revenue from Yichang Renfu's anesthesia segment in 2023, a 15.5% increase year-on-year [2]. R&D Investment - The company has made significant progress in its innovative drug development, with multiple drugs receiving clinical trial approvals in 2024 [2].